Telomir Pharmaceuticals Reports Key Type 2 Diabetes Reversal in Telomir-1 Preclinical Study

Building on their prior success in age-reversal science, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), an emerging leader in this field, has announced preclinical findings that affirm the efficacy of their proprietary molecule, Telomir-1, in addressing several key aspects of Type 2 diabetes mellitus. The study results highlight Telomir-1's ability to significantly lower fasting plasma glucose levels, improve oral glucose homeostasis, and reverse insulin resistance to near pre-diabetic levels. These effects were substantiated by improved Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) values, a widely recognized measure for evaluating insulin sensitivity and resistance.

The preclinical study, which utilized a zebrafish model of diabetes, demonstrated that Telomir-1's mechanism of action involves normalizing iron metabolism, thereby addressing oxidative stress and beta-cell damage. This novel approach sets Telomir-1 apart from existing diabetes treatments, which generally manage symptoms rather than targeting the underlying causes of the disease. The study's findings indicate that Telomir-1 not only normalizes blood glucose levels but also significantly reduces HOMA-IR values, indicating an improvement in insulin sensitivity.

Type 2 diabetes affects over 800 million adults worldwide and incurs an annual healthcare cost exceeding $966 billion. Current treatments primarily focus on managing blood glucose levels and alleviating symptoms. However, these therapies often come with limitations, including limited effectiveness on insulin resistance, gastrointestinal issues, hypoglycemia risks, cardiovascular complications, and weight gain. Telomir-1's potential to address the root causes of Type 2 diabetes offers a promising alternative.

Telomir Pharmaceuticals' Chairman and CEO, Erez Aminov, emphasized the broader implications of these findings, noting that Telomir-1 has shown potential not only in reversing age-related decline but also in addressing critical parameters of Type 2 diabetes. These preclinical results support Telomir’s broader vision of targeting the underlying causes of chronic diseases as part of their age-reversal research.

Telomir is advancing additional research to explore the full potential of Telomir-1. These efforts include studies on human progeria cell lines to assess its effects on accelerated aging, validation in diabetic mouse models, and investigations into its potential for treating Alzheimer’s disease, osteoarthritis, and various inflammatory conditions. Furthermore, Telomir-1's role in combating age-related oncological conditions is also under exploration.

The study's promising results were achieved in collaboration with Pentagrit, an India-based research organization. Telomir-1 was administered orally at different doses in zebrafish models induced with Type 2 diabetes through a high-calorie diet. The study assessed several key metabolic indicators, including fasting glucose levels, Oral Glucose Tolerance Test (OGTT) results, insulin concentrations, and HOMA-IR values. Key findings include the normalization of blood glucose and insulin levels, improved insulin sensitivity to near pre-diabetes values, enhanced glucose clearance, and increased survival rates in treated models.

Telomir Pharmaceuticals continues to pioneer age-reversal science with the goal of developing and gaining regulatory approval for Telomir-1, a molecule designed to lengthen the protective telomere caps of DNA. These caps play a crucial role in the aging process and the development of degenerative diseases. The company's broader aim is to promote longevity and enhance overall quality of life through innovative treatments that target the root causes of age-related conditions.

Telomir-1 is still in preclinical development and has not yet been tested in humans. The future development of Telomir-1 and its potential FDA approval remain contingent on further rigorous testing and validation steps.